University of South Florida

Digital Commons @ University of South Florida
Neurosurgery and Brain Repair Faculty
Publications

Neurosurgery and Brain Repair

2019

MicroRNA-133a and Myocardial Infarction
Yi Xiao
Central South University

Jiling Zhao
Central South University

Julian P. Tuazon
University of South Florida

Cesar V. Borlongan
University of South Florida, cborlong@usf.edu

Guolong Yu
University of South Florida

Follow this and additional works at: https://digitalcommons.usf.edu/nbr_facpub
Part of the Neurosurgery Commons

Scholar Commons Citation
Xiao, Yi; Zhao, Jiling; Tuazon, Julian P.; Borlongan, Cesar V.; and Yu, Guolong, "MicroRNA-133a and
Myocardial Infarction" (2019). Neurosurgery and Brain Repair Faculty Publications. 17.
https://digitalcommons.usf.edu/nbr_facpub/17

This Article is brought to you for free and open access by the Neurosurgery and Brain Repair at Digital Commons @
University of South Florida. It has been accepted for inclusion in Neurosurgery and Brain Repair Faculty
Publications by an authorized administrator of Digital Commons @ University of South Florida. For more
information, please contact scholarcommons@usf.edu.

Review

MicroRNA-133a and Myocardial Infarction

Cell Transplantation
2019, Vol. 28(7) 831–838
ª The Author(s) 2019
Article reuse guidelines:
sagepub.com/journals-permissions
DOI: 10.1177/0963689719843806
journals.sagepub.com/home/cll

Yi Xiao1, Jiling Zhao1, Julian P. Tuazon2,
Cesar V. Borlongan2, and Guolong Yu1

Abstract
Myocardial infarction (MI) is the leading cause of morbidity and mortality in the world. The infarcted heart displays typical cell
death cascades characterized by a loss of cells and fibrotic scarring in the myocardium. Cardiac hypertrophy and fibrosis largely
contribute to ventricular wall thickening and stiffening, altogether defining an adverse cardiac remodeling that ultimately leads
to impaired cardiac function and subsequent heart failure. Finding a strategy to promote therapeutic, instead of detrimental,
cardiac remodeling may pose as a potent MI treatment. Accumulating evidence shows that microRNAs (miRNAs) may play an
essential role in cardiovascular diseases. In particular, microRNA-133a (miR-133a) is one of the most abundant miRNAs in the
heart. Multiple studies have demonstrated that miR-133a participates in the early pathology of MI, as well as in subsequent
cardiac remodeling. In this review, we summarize recent research progress highlighting the regulatory effects of miR-133a in
ischemic myocardial diseases, such as inhibiting angiogenesis, apoptosis, fibrosis, hypertrophy, and inflammation, while promoting therapeutic cardiac remodeling. The goal is to elicit a critical discussion on the translational direction of miRNAmediated treatments towards a safe and effective MI therapy.
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Overview of MicroRNA-133a (miR-133a) in
the Heart
MicroRNAs (miRNAs) are endogenous, 19–22 nucleotide,
and non-coding single-stranded RNA molecules that are
important regulators of physiologic and pathologic conditions of the body. MiRNAs usually play critical roles in
regulating a range of cellular processes by posttranscriptional suppression of their target genes. Certain
miRNAs may be expressed in a tissue-specific pattern, such
as cardiac miRNAs (miR-1, miR133a, miR-208a/b, and
miR-499), which are abundantly expressed in the myocardium. There is mounting evidence that these miRNAs are
involved in heart development and certain cardiovascular
diseases, including myocardial infarction (MI), in both
experimental animals and patients (Table 1)1. MiR-133 is
transcribed from the same chromosomal loci as miR-1, and
miR-1 has expression levels during cardiac hypertrophy that
change in the opposite direction during myocardial infarction1,4. Of note, miR-133a is not only associated with heart
development and disease, but is also involved in various
cancers such as breast cancer and hepatocellular carcinoma21,22. In addition, miR-1 and miR-133a play a key role
in promoting cardiogenesis, heart function, and pathology.
While miR-1 and miR-133a predominantly control the early

stages of cardiogenesis by directing the commitment of
embryonic stem cells and mesodermal precursors to the
cardiac-specific muscle lineage, in the heart, miR-1 and
miR-133a also mediate cardiac conductance and automaticity by regulating all phases of the cardiac action potential1.
Particularly, miR-133a is essential for proper heart development as deletion of both miR-133a genes leads to anomalous
heart smooth muscle gene expression, deviant apoptosis and
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Table 1. Role/Expression of MicroRNAs in the Heart.
microRNA Role/Expression
miR-1

Early cardiogenesis. Direct commitment of cells to
cardiac-specific muscle lineage. Mediate cardiac
conductance and automaticity, and cardiac action
potential. Promotes apoptosis and worsens
oxidative stress in damaged cardiomyocytes1–3.
Increased in the heart and elevated in circulation
after myocardial infarction. Down-regulated in
hypertrophic hearts4,5.
miR-133a Early cardiogenesis. Direct commitment of cells to
cardiac-specific muscle lineage. Mediate cardiac
conductance and automaticity, and cardiac
action potential1. Inhibits apoptosis in
damaged cardiomyocytes and adverse cardiac
remodeling6,7–9,10,11–13. Down-regulated in the
infarct area and increased in circulation after
myocardial infarction. Decreased in hypertrophic
hearts4,14,15–17.
miR-208a/b Late cardiogenesis. Specify slow/fast muscle fibers and
direct differentiation of cardioblasts to
cardiomyocytes. Control sarcomeric contractile
protein expression1. MiR-208a overexpression
promotes cardiac hypertrophy18. Reduced in the
heart and increased in circulation after myocardial
infarction. Up-regulated in hypertrophic hearts1,4.
miR-499
Late cardiogenesis. Specify slow/fast muscle fibers and
direct differentiation of cardioblasts to
cardiomyocytes. Control sarcomeric contractile
protein expression1. Expresses cardioprotective
properties19. Inhibit myocyte enhancer factor 2C20.
Increased in circulation after myocardial infarction1.

proliferation patterns, lethal ventricular septal defects, and
disorganized sarcomeres23. It is also interesting to note that
miR-133a and miR-1 may have opposite roles during cardiac
differentiation24, and that miR-133 inhibits apoptosis while
miR-1 promotes apoptosis and oxidative stress in damaged
cardiomyocytes1–3. Patients with MI may develop ventricular fibrillation (VF), a vital cause of death, and downregulating miR-133a/b may contribute to the development
of VF in patients with MI14. Furthermore, over-expression of
miR-133 improves cardiac function in a rat model of MI
such as by increasing the left ventricular ejection fraction
(LVEF) and fractional shortening (FS)25.

MiR-133a as a Potential Diagnostic
Biomarker of Acute MI
MiR-133a is down-regulated in both the infarcted region and
the border zone of the heart in MI patients, as well as in
experimental animals14,15. In contrast, the expression level
of miR-133a in serum is elevated significantly in patients
with acute myocardial infarction (AMI) or with unstable
angina pectoris5,16,17. Additionally, miR-133a levels in
serum are significantly related to all-cause mortality in acute
coronary syndrome (ACS) patients16. In 2011, Kimura et al.
first measured the levels of circulating miR-1 and miR-133a
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associated with cardiovascular diseases, and demonstrated
that the levels of circulating miR-1 and miR-133a are
elevated early after the onset of chest pain when there is
no up-regulation in serum creatine phosphokinase (CK or
CPK) or cardiac Troponin T (cTnT), and that serum miR-133a
levels are sensitive to myocardial injury compared with miR-1
levels5. Increased levels of circulating miR-133a are found in
exosomes, which implies that the living myocardium may be
the source of circulating miR-133a5. Moreover, elevated levels
of circulating miR-133a are strongly associated with AMI
diagnosis. In addition to traditional markers for clinical prognosis in AMI patients, the concentration of miR-133a may also
provide prognostic information, perhaps even earlier than these
traditional markers5,26. Indeed, based on their tissue specificity,
cardiomyocyte-enriched miRNAs such as miR-1, miR208a,
miR-208b, miR-133a, miR-133b, and miR-499 have been
proposed as potential diagnostic markers in patients with
AMI16,27–29. Nevertheless, circulating levels of miR-133a and
miR-423-5p have failed as useful biomarkers of left ventricular
(LV) remodeling after MI30.

MiR-133a Modulating Angiogenesis Act as
Angio-miR
The sprouting of new blood vessels by angiogenesis is key in
physiologic vascular development and pathological homeostasis. Abnormal angiogenesis leads to severe pathological
conditions such as ischemia and cancer. Recently, miRNAs
have been implicated to be involved in certain angiogenic
factors and signaling pathways, and use small non-coding
RNAs to promote or suppress angiogenic processes. For
instance, the up-regulation of miR-133a induced by diabetes
mellitus impairs angiogenesis in peripheral arterial disease
(PAD) by reducing NO in endothelial cells31. Additionally,
miR-133a suppresses angiogenesis of endothelial cells including proliferation rate, cell viability, and migration activity via
targeting of VEGFR2 and FGFR132. MiR-133a is reduced
when vascular smooth muscle cells (VSMCs) are inclined to
proliferate in vitro and following vascular injury in vivo, and
increase when VSMCs are coaxed back to quiescence in vitro
and in vivo. In addition, miR-133a interference and overexpression experiments show that miR-133a plays a mechanistic role in VSMC proliferation. Among the possible targets
of miR-133a, the most reliable is the serum response factor
(SRF), which plays a critical role in muscle proliferation and
differentiation depending on its association with co-factors
such as myocardin, HOP, and Elk-133–37. Accordingly,
adeno-miR-133a suppresses while anti-miR-133a improves
VSMC proliferation and migration in vitro and in vivo, by
suppressing the expression of the transcription factor, Sp-138.

MiR-133a Reduces Hypoxia-Induced
Apoptosis in Cardiac Myocytes
Apoptosis, also called programmed cell death, plays a key
role in both the physical development and the pathology of a
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variety of cells and tissues. Myocardial hypoxia is a major
cause of cardiac dysfunction as it triggers cell injury and
apoptosis39. Growing evidence indicates that miRNAs are
of vital importance in regulating cardiovascular diseases,
necessitating the demonstration of the molecular mechanism
by which miRNAs control apoptosis and the identification of
their direct and indirect targets40–43. MiR-133a is among the
most abundant of the miRNAs present in the normal heart,
and significant changes in the expression of miR-133a are
observed in response to anoxia stress44. Interestingly, miR133a is significantly down-regulated in hypoxic H9c2 cells,
a type of SD rat cardiomyocyte, and the over-expression of
miR-133a suppresses hypoxia-induced apoptosis and
enhances cardiomyocyte survival6,45–47. Additionally, miR133a is an apoptosis suppressor in myocardial ischemic postconditioning (IPost), inhibiting TAGLN2, HSP60, HSP70,
Apaf-1, caspase-3/8/9 expression, and promoting antiapoptotic protein Bcl-2 expression6,7–9. Ischemia and reperfusion injury (I/R injury) increases apoptosis via elevated
expression of pro-apoptotic genes like caspase-9, and
reduces miR-1 and miR-133 levels. In contrast, IPost upregulates miR-133a, which decreases caspase-9 expression,
and, consequently, decreases apoptosis of cardiomyocytes
under I/R injury. Thus, myo-miRNAs miR-1 and miR133a may play an important role in IPost protection by regulating apoptosis-related genes, such as caspase-97.

MiR-133a Over-Expression Protects
Against Cardiac Fibrosis Post-MI
The main determinants of tissue fibrosis are an activated
transforming growth factor-b (TGF-b) signaling cascade and
the accumulation of increased extracellular matrix (ECM)
proteins such as fibronectin (FN1) and collagen 1 alpha
1 V (COL4a1)48. MiR-133a, along with other transcription
factors or miRNAs, can induce myocardial transdifferentiation of cardiac fibroblasts by inhibiting TGF-b signaling or
the expression of certain factors that promote fibrosis, such
as snail-1 expression49–51, as well as improve cardiac function and fibrosis by inhibiting Akt in heart failure10. Connective tissue growth factor (CTGF) is another important
target of miR-133a and a key molecule in the process of
fibrosis. Thus, CTGF appears to be a potential therapeutic
target in MI, as miR-133a can potentially protect against
cardiac fibrosis by decreasing CTGF expression in the
heart52. Moreover, the SRF/CTGF/miR-133a axis plays an
important role in regulating cardiac fibrosis53 and miR-133a
could be a potential therapeutic target for diabetes-induced
cardiac fibrosis and related cardiac dysfunction48.

MiR-133a Represses Cardiac Hypertrophy
MiR-133a has potential regulatory roles in cardiac hypertrophy. Activation of NFAT (nuclear factor of activated T
cells)-mediated hypertrophic signaling is a key regulatory
response to hypertrophic stimuli. NFATc4, a hypertrophy-
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associated mediator, is a negatively regulated target of miR133a54. Additionally, in vitro over-expression of miR-133 or
miR-1 could inhibit cardiac hypertrophy. In contrast, inhibition of miR-133 by ‘decoy’ sequences induces hypertrophy,
which is more pronounced than hypertrophy generated with
common inducers. In vivo inhibition of miR-133 by a single
transfection of an antagomir causes sustained and marked
cardiac hypertrophy. RhoA, a GDP-GTP exchange protein
regulating cardiac hypertrophy; Cdc42, a signal transduction
kinase involved in hypertrophy; and Nelf-A/WHSC2, a
nuclear factor implicated in cardiogenesis, have been identified as specific targets of miR-13311. In addition to MI,
circulating miR-133a could also serve as a biomarker for
predicting cardiac hypertrophy in chronic hemodialysis
patients and after valve replacement surgery in patients with
aortic stenosis12,13.

MiR-133a Promotes Regeneration and
Cardiac Programming Post-MI
Regeneration of the infarcted heart with new, functional
cardiomyocytes remains challenging, but promising. Transplantation of cardiac stem cells (CSCs) or progenitor cells
has been regarded as a potential therapeutic option for myocardial infarction patients. At present, cell therapy
approaches with various types of mature or stem cell patients
have produced modest improvements. Among them, resident
CSCs/CPCs are a promising option. The great beneficial
cardiac-specific effect of cardiac miRNAs including miR133a is very helpful for enhancing the regenerative properties and survival of transplanted stem cells and cardiac
progenitor cells, and for reprogramming mature noncardiac cells to cardiomyocytes1. Both miR-1 and miR133a progressively increase early during in vitro cardiac
differentiation of adult CPCs, but only miR-133a expression
increases under in vitro oxidative stress. miR-1 promotes
differentiation of CPCs, while over-expressed miR-133a
protects CPCs from cell death by targeting the proapoptotic genes Bim and Bmf51. As a result, miR-133aCPCs improve cardiomyocyte proliferation post-MI. The
beneficial effects of miR-133a-CPCs seem to correlate with
the enhanced expression of various related paracrine factors
and the valid cooperative secretion of miR-133a via exosomal transport51. Direct reprogramming refers to changing
mature cells from one lineage to another without passing
through a stem cell state, and cardiac reprogramming indicates the conversion of other cells into cardiomyocytes. A
combination of cardiac-miRNA-1, 133, 208, and 499 are
capable of promoting the direct cardiac reprogramming of
fibroblasts to cardiomyocyte-like cells in vitro55. Therein,
miR-133 promotes cardiac reprogramming by targeting
Snai-1 and silencing fibroblast signatures50. Growing evidence demonstrates that muscle specific miRNAs, also
defined as myo-miRs, function as a control center in directing diverse biological processes during myogenic proliferation and differentiation56, and the most widely studied ones
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Fig 1. Therapeutic cardiac remodeling via transplantation of microRNA-133a (miR-133a) and stem cells. Myocardial infarction (MI) can lead
to adverse cardiac remodeling and promote the development of hypertrophy and fibrosis. Transplantation of stem cells transfected with
miR-133a in MI hearts can promote therapeutic cardiac remodeling to combat these detrimental effects and may be more effective than
transplantation of stem cells alone.

are members of the miR-1, miR-206, and miR-133 families33,57. Additionally, the myogenic transcription factors
myogenin and myogenic differentiation 1 (MyoD) bind to
regions upstream of the miR-1 and miR-133 stem loop,
thereby providing a molecular explanation for the observed
induction during myogenesis. An increase in the levels of
miR-1, miR-133, and miR-206 is seen during myogenesis58,
indicating miR-133’s role in the process.

The Role of miR-133a in Anti-Inflammation
Post-MI
Endomyocardial miR-133a levels correlate with myocardial
inflammation, such as macrophage infiltration 59. Overexpressing miR-133a reduces inflammatory cell infiltration
in the heart at 7 and 28 days post-MI25. In contrast, some
clinical investigations show that serum miR-133a levels
are significantly increased in critical illness and sepsis, are
correlated with the severity of the disease, and predict an
unfavorable outcome for critically ill patients60. Indeed,
miR-133a may also serve as a pro-inflammatory miRNA,
warranting more direct studies to confirm or disprove this
conclusion.

MiR-133a and Stem Cell Transplantation
in MI
Of note, transplanting stem cells into hearts afflicted with MI
may improve the outcome of the condition. Indeed, bone

marrow mesenchymal stem cells (MSCs) grafted into the
MI heart generate healthy cardiomyocytes, increase cardiac
function, promote angiogenesis, and decrease detrimental
remodeling 61,62 . However, ischemic conditions in the
infarcted heart hinder the survival of the transplanted stem
cells and reduce these beneficial effects. MiRNAs play
important roles in regulating cell apoptosis, differentiation,
and proliferation and appear promising in bolstering the survival and efficacy of these transplanted stem cells9. In particular, miR-133a protects CPCs against apoptosis 51 ,
increases the proliferation of myoblasts33, and curtails cardiac remodeling, hypertrophy, and fibrosis9. The presence or
absence of certain miRNAs such as miR-27b enables senescence to be modulated in MSCs59, and miRNAs such as
miR-21 are critical for facilitating MSC-induced protection
of human bronchial epithelial cells under hypoxic conditions63. Moreover, let-7-5p miR appears to be critical for
enabling extracellular vesicles derived from Wharton’s jelly
MSCs to prevent the apoptosis of neurons under perinatal
hypoxia-ischemia64. Interestingly, transplantation of MSCs
transfected with miR-133a in an MI heart enhances graft
survival and cardiac function, and reduces cardiac fibrosis
compared with transplantation with non-transfected stem
cells9 (Fig. 1). Additionally, in a rat myocardial infarct
model, injecting MSCs transfected with the miR-133a agomir increases cardiac function and decreases MSC apoptosis,
inflammation, and infarct size, relative to injecting MSCs
alone. In contrast, injecting MSCs transfected with the
miR-133a antagomir increases MSC apoptosis 25 .
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Table 2. Regulatory Roles of miR-133a in Myocardial Infarction.
Reported miR-133a action
in the heart
Targets
Inhibits angiogenesis

Inhibits apoptosis

Inhibits fibrosis

Inhibits hypertrophy

Induces cardiac
reprogramming

VEGFR2
FGFR1
Sp-1
SRF
TAGLN2
HSP60
HSP70
caspase-3/
8/9
Apaf-1
Bcl-2
TGF-b
Snail-1
CTGF
RhoA
Cdc42
Nelf-A/
WHSC2
NFATc4
Snail-1
Bim
Bmf
MyoD

References
D’Alessandra et al.28
D’Alessandra et al.28
Zhang et al.34
Chen et al.31
Li et al.41
Feng et al.45
Feng et al.45
Li et al.6, Feng et al.45,
Zhang et al.46
Zhang et al.46
Li et al.41
He et al.7, Xu et al.8
Xu et al.8
Dal-Pra et al.49, Muraoka
et al.50
Sang et al.10
Sang et al.10
Sang et al.10
51

Izarra et al.
Xu et al.8
Dakhlallah et al.9
Dakhlallah et al.9
Garcia et al.13

Furthermore, overexpression of miR-133a promotes the differentiation of human bone marrow-derived MSCs to cardiac
cells that express markers such as cTnT and b-MHC, and
executes these changes by targeting epidermal growth factor
receptor65. Thus, miR-133a can be utilized in stem cell
therapies for MI to augment the survival of grafted cells and
increase treatment effectiveness, possibly by enabling more
transplanted stem cells to differentiate into healthy cardiomyocytes, or by contributing additional cardioprotective
benefits. Similarly, the survival rate and ability of transplanted cells to resist host-mediated immune responses may
also be strengthened by employing exosomes derived from
MSCs that overexpress indoleamine 2,3-dioxygenase 166,67.

Conclusion and Perspectives
Collectively, these lines of evidence imply the potential of
miR-133a as a promising therapeutic target in the treatment
of MI. Nevertheless, the roles of miR-133a in myocardial
infarction remain largely unknown. So far, studies have
demonstrated that miR-133a induces positive effects on
infarcted hearts in regard to angiogenesis, inflammation,
apoptosis, fibrosis, hypertrophy, and cardiac programming
(Table 2). However, we cannot conclude whether miR-133a
is completely beneficial or not to the infarcted heart. The
mechanisms of miR-133a-mediated cardiomyopathy are
extremely complex because miR-133a targets the upstream
molecules of various critical transcription factors. Moreover,
numerous studies have shown that infarcted myocardium

experience decreased miR-133a compared with normal
areas, and up-regulating miR-133a expression through
genetic manipulation techniques are beneficial for the heart
under ischemic injury. These findings indicate that certain
levels of miR-133a may be of vital importance in maintaining the balance of cardiac function. Therefore, the main aim
of miR-133a intervention is to restore miR-133a levels in the
myocardium, which is influenced by cardiac stress. In addition to the intracellular function of miR-133a, increasing
evidence has revealed that circulating miR-133a can be used
as a potential MI biomarker. Thus, it may be worthwhile to
consider that miR-133a, in addition to being potential therapeutic target, can also be used as a diagnostic biomarker.
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